Roche’s success in two Phase III studies with its anti-CD20 antibody ocrelizumab against Merck Serono SA’s mainstay interferon beta-1a treatment Rebif in multiple sclerosis is a shot in the arm for the company’s diversification goals, including neuroscience, following some high-profile failures.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?